8,000 Shares in ARK Genomic Revolution ETF (BATS:ARKG) Acquired by Zuckerman Investment Group LLC

Zuckerman Investment Group LLC bought a new stake in shares of ARK Genomic Revolution ETF (BATS:ARKG) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 8,000 shares of the company’s stock, valued at approximately $188,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ARKG. JPMorgan Chase & Co. raised its position in shares of ARK Genomic Revolution ETF by 31.0% in the third quarter. JPMorgan Chase & Co. now owns 2,955,279 shares of the company’s stock valued at $75,655,000 after purchasing an additional 698,701 shares during the period. Barclays PLC increased its position in ARK Genomic Revolution ETF by 252.7% in the 3rd quarter. Barclays PLC now owns 285,108 shares of the company’s stock valued at $7,299,000 after acquiring an additional 204,283 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in ARK Genomic Revolution ETF in the fourth quarter worth about $2,027,000. Tallon Kerry Patrick bought a new position in shares of ARK Genomic Revolution ETF in the 4th quarter worth $637,000. Finally, Captrust Financial Advisors acquired a new stake in ARK Genomic Revolution ETF in the third quarter worth $485,000.

ARK Genomic Revolution ETF Price Performance

BATS ARKG opened at $20.56 on Thursday. The business has a 50 day simple moving average of $23.98 and a 200 day simple moving average of $24.58. ARK Genomic Revolution ETF has a 52-week low of $17.51 and a 52-week high of $31.16.

About ARK Genomic Revolution ETF

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.